Severe Neutropenia in Infants With Congenital Cytomegalovirus on Antiviral Therapy.

AIM: To describe European real-life experience of severe neutropenia (SN) during ganciclovir (GCV) and/or valganciclovir (VGCV) treatment in infants with congenital cytomegalovirus (cCMV) infection and identify risk factors associated with the development of SN. METHODS: A multicenter retrospective...

Descripción completa

Detalles Bibliográficos
Autores: Papaevangelou V, Pedrero-Tomé R, Syridou G, Baquero-Artigao F, Rodríguez-Molino P, Del Rosal T, Noguera-Julián A, Ríos-Barnés M, Fortuny C, Villaverde S, Frick MA, Vallejo BÁ, Soler-Palacín P, Saavedra J, Rincón E, Karagiannidou S, Busselo IS, Zuriarrain OM, Calderón EM, Tagarro A, Malumbres M, Colino E, Llanos EG, Ruiz AM, Mateos MS, Espuny XB, Alonso-Ojembarrena A, Ferreras-Antolin L, Pérez IC, Posse AF, Lyall H, Blázquez-Gamero D
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p28948
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=28948
Access Level:acceso abierto
Palabra clave:antiviral treatment
congenital cytomegalovirus
neutropenia
prematurity
Descripción
Sumario:AIM: To describe European real-life experience of severe neutropenia (SN) during ganciclovir (GCV) and/or valganciclovir (VGCV) treatment in infants with congenital cytomegalovirus (cCMV) infection and identify risk factors associated with the development of SN. METHODS: A multicenter retrospective cohort study from the European cCMVnet registry included infants with confirmed cCMV infection treated since 2011 with GCV and/or VGCV. Details of treatment, including age at initiation, route of administration and duration, are described. Prevalence and risk factors associated with the development of SN, defined as neutrophil count of <500 cells/mm 3 , were analyzed. RESULTS: Overall, 566 children with confirmed cCMV treated with antivirals were included; 165 (29.7%) were born prematurely (gestational age <37 weeks). Administration of intravenous GCV, alone or in combination with oral VGCV, was associated with prematurity and date of birth before 2017. SN occurred in 102 infants (18%). Multivariate logistic regression analysis identified 2 independent risk factors for the development of SN: prematurity almost doubled the risk of developing SN [odds ratio (OR) = 1.961; 95% confidence interval (CI): 1.163-3.300], while the risk of developing SN increased by 11% for every 1000 neutrophils decrease in the absolute neutrophil count at baseline (OR = 1.104; 95% CI: 1.031-1.192). When term newborns were analyzed alone, baseline absolute neutrophil count remained an important risk factor for developing SN. CONCLUSIONS: In children with cCMV treated with GCV/VGCV prematurity and low pretreatment neutrophil counts are associated with an increased risk of developing SN. This is important for patient management, and when informing parents about treatment side effects.

Similares en LA Referencia